Unique ID issued by UMIN | UMIN000058134 |
---|---|
Receipt number | R000066360 |
Scientific Title | Evaluation of the effectiveness of alternating magnetic field therapy device (AT-04) for chemotherapy-induced peripheral neuropathy |
Date of disclosure of the study information | 2025/07/01 |
Last modified on | 2025/06/08 13:32:12 |
Examination of the effectiveness of the medical device AT-04 for peripheral neuropathy caused by anti-cancer drugs
Examination of the effectiveness of the medical device AT-04 for peripheral neuropathy caused by anti-cancer drugs
Evaluation of the effectiveness of alternating magnetic field therapy device (AT-04) for chemotherapy-induced peripheral neuropathy
Evaluation of the effectiveness of alternating magnetic field therapy device (AT-04) for chemotherapy-induced peripheral neuropathy
Japan |
Chemotherapy-Induced Peripheral Neuropathy
Urology |
Others
NO
The objective is to evaluate the efficacy and safety of alternating magnetic field therapy device AT-04 for the treatment of chemotherapy-induced peripheral neuropathy.
Safety,Efficacy
Exploratory
Change in Pain and Numbness Numeric Rating Scale (NRS) at the Final Measurement
Change in Pain Numeric Rating Scale (NRS) at Each Observation Time Point
Change in EORTC QLQ-C30 and QLQ-CIPN20 Scores and Subscores at Each Observation Time Point
Patient Global Impression of Change (PGI-C) at Each Observation Time Point
Incidence of Adverse Events (CTCAE v.5.0)
Incidence of Device Malfunctions
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Device,equipment |
AT-04 group: Treatment with the AT-04 alternating magnetic field therapy device. The device's leads were placed on four locations: both armpits and both groins, or the palms of both hands and the soles of both feet. The device was used for 30 minutes each time, at least twice a day (maximum of two hours), for 84 days.
Sham machine group: Treatment with the Sham machine.The device's leads were placed on four locations: both armpits and both groins, or the palms of both hands and the soles of both feet. The device was used for 30 minutes each time, at least twice a day (maximum of two hours), for 84 days.
18 | years-old | <= |
Not applicable |
Male and Female
Patients with a 24-hour average pain NRS of 4/10 or more due to CIPN
Patients with peripheral sensory neuropathy of grade 1 or more in any limb based on CTCAE v5.0
Patients with an ECOG performance status of 0 to 2
Patients with a predicted prognosis of 12 weeks or more
Patients who have provided written informed consent
Patients who disagreed with the informed consent
Patients who are deemed inappropriate by the principal investigator or subinvestigator.
30
1st name | SUNAO |
Middle name | |
Last name | SHOJI |
Tokai University
Department of Urology
259-1193
Shimokasuya 143, Isehara, Kanagawa, Japan
0463-93-1121
sunashoj@tokai.ac.jp
1st name | SOICHIRO |
Middle name | |
Last name | YUZURIHA |
Tokai University
Department of Urology
259-1193
Shimokasuya 143, Isehara, Kanagawa, Japan
0463-93-1121
ys6683@tokai.ac.jp
Tokai University
Tokai University
Self funding
Institutional Review Board for Clinical Research, Tokai University
Shimokasuya 143, Isehara, Kanagawa, Japan
0463-93-1121
ys6683@tokai.ac.jp
NO
2025 | Year | 07 | Month | 01 | Day |
Unpublished
Open public recruiting
2024 | Year | 12 | Month | 02 | Day |
2025 | Year | 02 | Month | 18 | Day |
2025 | Year | 05 | Month | 01 | Day |
2027 | Year | 03 | Month | 31 | Day |
2025 | Year | 06 | Month | 10 | Day |
2025 | Year | 06 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066360